Muscarinic receptor genotype

Published: 18-07-2007 Last updated: 08-05-2024

Objective: To determine whether genotype of the promoter polymorphism is associated with

alterations of mRNA expression of the M2 receptor

Ethical review Approved WMO

Status Pending

Health condition type Gastrointestinal motility and defaecation conditions

Study type Observational invasive

Summary

ID

NL-OMON30915

Source

ToetsingOnline

Brief title

Muscarinic receptor genotype

Condition

- Gastrointestinal motility and defaecation conditions
- Bladder and bladder neck disorders (excl calculi)
- Bronchial disorders (excl neoplasms)

Synonym

benign prostatic hypertrophia, overactive bladder

Research involving

Human

Sponsors and support

Primary sponsor: Academisch Medisch Centrum

Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: muscarinic receptor genotype mRNA

Outcome measures

Primary outcome

Main study parameters/endpoints: Genotype for the polymorphism in the M2 receptor gene promoter will be related to abundance of M2 receptor mRNA in prostatic tissue; mRNA for housekeeping genes and for other muscarinic receptor subtypes will be internal controls

Secondary outcome

not applicable

Study description

Background summary

Rationale: Polymorphisms have been described in the promoter of the gene encoding the M2 muscarinic acetylcholine receptor, which were reported to be associated with increased transcriptional activity in airway cells. Whether this also applies to the lower urinary tract is unclear.

Group benefit appears possible if the results support the hypothesis that genotype determines phenotype (receptor expression) with regard to the M2 receptor gene; in this case indication and/or dosage of therapeutics acting on M2 receptors may eventually be found to be affected by genotype.

Study objective

Objective: To determine whether genotype of the promoter polymorphism is associated with alterations of mRNA expression of the M2 receptor

Study design

Study design: Cross-sectional, observational study

Study burden and risks

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Burden and risk are neglible as only a small

amount of blood (single sample of 2 ml) will be used, obtained on an occasion where venipuncture is performed for medical reasons. The prostatic tissue to be used will be tissue removed for therapeutic reasons but not required for pathological analysis (*discarded tissue*).

Contacts

Public

Academisch Medisch Centrum

Meibergdreef 9 1105 AZ Amsterdam-zuidoost Nederland **Scientific**

Academisch Medisch Centrum

Meibergdreef 9 1105 AZ Amsterdam-zuidoost Nederland

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

Male patients treated in the department of Urology of the Amsterdam Medical Center (AMC) of any age. Any patient that receives any kind of treatment in which prostate tissue is harvested and and not required for pathological analysis.

Exclusion criteria

none

Study design

Design

Study type: Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Other

Recruitment

NL

Recruitment status: Pending

Start date (anticipated): 01-06-2007

Enrollment: 200

Type: Anticipated

Ethics review

Approved WMO

Application type: First submission

Review commission: METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

CCMO NL17808.018.07